Patents by Inventor Ryan P. Bennett

Ryan P. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating coronavirus infections
    Patent number: 11779585
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: October 10, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • METHOD FOR TREATING ARENAVIRIDAE INFECTIONS
    Publication number: 20230285434
    Abstract: Disclosed herein are methods, compositions and kits for treating and inhibiting Arenaviridae virus infections and their associated diseases, such as Lassa fever caused by the Lassa virus (LASV).
    Type: Application
    Filed: April 14, 2021
    Publication date: September 14, 2023
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Method for treating coronavirus infections
    Patent number: 11738025
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: August 29, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • METHOD FOR TREATING POXVIRIDAE INFECTIONS
    Publication number: 20230233591
    Abstract: Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop-gap methods for controlling the spread of Poxviridae virus infections.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 27, 2023
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Methods of treating and inhibiting Ebola virus infection
    Patent number: 11617753
    Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 4, 2023
    Assignees: OYAGEN, INC., The United States of America, as represented by the Secretary of Health and Human Services
    Inventors: Harold C. Smith, Ryan P. Bennett, Peter Jahrling
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20220378815
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20220000860
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 6, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • Compounds, compositions, and methods for treating human immunodeficiency virus
    Patent number: 11116762
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: September 14, 2021
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20210236497
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: April 16, 2020
    Publication date: August 5, 2021
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION
    Publication number: 20200338067
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: March 15, 2020
    Publication date: October 29, 2020
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION
    Publication number: 20200188404
    Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.
    Type: Application
    Filed: November 6, 2017
    Publication date: June 18, 2020
    Inventors: Harold C. SMITH, Ryan P. BENNETT, Peter JAHRLING
  • Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association
    Patent number: 10588902
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 17, 2020
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20190350925
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Application
    Filed: January 2, 2018
    Publication date: November 21, 2019
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION
    Publication number: 20160143900
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: June 24, 2014
    Publication date: May 26, 2016
    Applicant: OyaGen, Inc.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF
    Publication number: 20150272959
    Abstract: The present invention relates to the use of small molecules as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: October 4, 2013
    Publication date: October 1, 2015
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett